Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus

Lupus Science and Medicine

Volumn 2, Issue 1, 2015, Pages

  Mackay, Meggan ^a   Tang, Chris C ^a   Volpe, Bruce T ^a   Aranow, Cynthia ^a   Mattis, Paul J ^a   Korff, Ricki A ^a   Diamond, Betty ^a   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FLUORODEOXYGLUCOSE F 18; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ANTIBODY TITER; ARTICLE; ATTENTION; BRAIN METABOLISM; BRAIN REGION; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL DISEASE; HIPPOCAMPUS; HUMAN; HYPERMETABOLISM; MALE; MEDICAL HISTORY; NEUROPSYCHOLOGICAL TEST; ORBITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; WORKING MEMORY;

EID: 84946732996     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2014-000074     Document Type: Article

References (53)

1. Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001;57:496-500.
2. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214-20.
3. Nowicka-Sauer K, Czuszynska Z, Smolenska Z, et al. Neuropsychological assessment in systemic lupus erythematosus patients: clinical usefulness of first-choice diagnostic tests in detecting cognitive impairment and preliminary diagnosis of neuropsychiatric lupus. Clin Exp Rheumatol 2011;29:299-306.
4. Unterman A, Nolte JES, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: A meta-analysis. Semin Arthritis Rheum 2011;41:1-11.
5. Stojanovich L, Zandman-Goddard G, Pavlovich S, et al. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 2007;6:421-6.
6. Appenzeller S, Cendes F, Costallat LT. Cognitive impairment and employment status in systemic lupus erythematosus: A prospective longitudinal study. Arthritis Rheum 2009;61:680-7.
7. Jonsen A, Bengtsson AA, Nived O, et al. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology (Oxford) 2002;41:1308-12.
8. Carbotte RM, Denburg SD, Denburg JA. Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J Rheumatol 1995;22:863-7.
9. Hanly JG, Hong C, Smith S, et al. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999;42:728-34.
10. Hay EM, Huddy A, Black D, et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis 1994;53:298-303.
11. Holliday SL, Navarrete MG, Hermosillo-Romo D, et al. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus 2003;12:697-703.
12. Petri M, Naqibuddin M, Carson KA, et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol 2010;37:2032-8.
13. Faust TW, Chang EH, Kowal C, et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci USA 2010;107:18569-74.
14. Huerta PT, Kowal C, DeGiorgio LA, et al. Immunity and behavior: Antibodies alter emotion. Proc Natl Acad Sci USA 2006;103:678-83.
15. Kowal C, DeGiorgio LA, Lee JY, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006;103:19854-9.
16. Lauvsnes MB, Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol 2012;259:622-9.
17. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008;58:1130-5.
18. Fragoso-Loyo H, Cabiedes J, Orozco-Narváez A, et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS ONE 2008;3:e3347.
19. Yoshio T, Onda K, Nara H, et al. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2006;54:675-8.
20. Husebye ES, Sthoeger ZM, Dayan M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1210-13.
21. DeGiorgio LA, Konstantinov KN, Lee SC, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189-93.
22. Banks WA, Erickson MA. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis. 2010;37:26-32.
23. Hawkins BT, Abbruscato TJ, Egleton RD, et al. Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res 2004;1027:48-58.
24. Reijerkerk A, Kooij G, van der Pol SM, et al. The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. J Neurochem 2010;113:447-53.
25. Verma S, Nakaoke R, Dohgu S, et al. Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav Immun 2006;20:449-55.
26. Mackay M, Bussa MP, Aranow C, et al. Differences in regional brain activation patterns assessed by functional magnetic resonance imaging in patients with Systemic Lupus Erythematosus stratified by disease duration. Mol Med 2011;17:1349-56.
27. Kao CH, Ho Y-J, Lan J-L, et al. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum 1999;42:61-8.
28. Komatsu N, Kodama K, Yamanouchi N, et al. Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Eur Neurol 1999;42:41-8.
29. Otte A, Weiner SM, Peter HH, et al. Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: A controlled positron emission tomography study. Eur J Nucl Med 1997;24:787-91.
30. Weiner SM, Otte A, Schumacher M, et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 2000;59:377-85.
31. Lee SW, Park M-C, Lee S-K, et al. The efficacy of brain (18) F-fluorodeoxyglucose positron emission tomography in neuropsychiatric lupus patients with normal brain magnetic resonance imaging findings. Lupus 2012;21:1531-7.
32. Ramage AE, Fox PT, Brey RL, et al. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. Arthritis Rheum 2011;63:3048-57.
33. [No authors listed]. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
34. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
35. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
36. Roebuck-Spencer TM, Yarboro C, Nowak M, et al. Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:434-41.
37. Antonchak MA, Saoudian M, Khan AR, et al. Cognitive dysfunction in patients with systemic lupus erythematosus: A controlled study. J Rheumatol 2011;38:1020-5.
38. Adhikari T, Piatti A, Luggen M. Cognitive dysfunction in SLE: development of a screening tool. Lupus 2011;20:1142-6.
39. Gaynor B, Putterman C, Valadon P, et al. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci USA 1997;94:1955-60.
40. Ma Y, Tang C, Spetsieris PG, et al. Abnormal metabolic network activity in Parkinson's disease: Test-retest reproducibility. J Cereb Blood Flow Metab 2007;27:597-605.
41. Fitzgibbon BM, Fairhall SL, Kirk IJ, et al. Functional MRI in NPSLE patients reveals increased parietal and frontal brain activation during a working memory task compared with controls. Rheumatology (Oxford) 2008;47:50-3.
42. Rocca MA, Agosta F, Mezzapesa DM, et al. An fMRI study of the motor system in patients with neuropsychiatric systemic lupus erythematosus. Neuroimage 2006;30:478-84.
43. Mackay M, Bussa MP, Aranow C, et al. Differences in regional brain activation patterns assessed by functional magnetic resonance imaging in patients with systemic lupus erythematosus stratified by disease duration. Mol Med 2011;17:1349-56.
44. Vo A, Volpe BT, Tang CC, et al. Regional brain metabolism in a murine systemic lupus erythematosus model. J Cereb Blood Flow Metab 2014;34:1315-20.
45. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narváez A, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007;56:1242-50.
46. Katsumata Y, Harigai M, Kawaguchi Y, et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol 2007;34:2010-17.
47. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000;9:498-503.
48. Nishimura K, Harigai M, Omori M, et al. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology 2008;33:395-403.
49. Appenzeller S, Li LM, Costallat LT, et al. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: A proton MRS study. Brain 2005;128(Pt 12):2933-40.
50. Stuss DT. Functions of the frontal lobes: relation to executive functions. J Int Neuropsychol Soc 2011;17:759-65.
51. LeDoux JE. Emotion circuits in the brain. Annu Rev Neurosci 2000;23:155-84.
52. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends Neurosci 2009;32:548-57.
53. Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum 2007;56:265-73.